AR063507A1 - Derivados del fluoreno, composiciones que los contienen y uso como anticancerigenos - Google Patents
Derivados del fluoreno, composiciones que los contienen y uso como anticancerigenosInfo
- Publication number
- AR063507A1 AR063507A1 ARP070104666A ARP070104666A AR063507A1 AR 063507 A1 AR063507 A1 AR 063507A1 AR P070104666 A ARP070104666 A AR P070104666A AR P070104666 A ARP070104666 A AR P070104666A AR 063507 A1 AR063507 A1 AR 063507A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- conh2
- banerigens
- fluorene
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Het representa un heterociclo mono o bicíclico, de 1 a 4 heteroátomos elegidos entre N, O o S, sustituIdo opclonalmente; R1 representa X-(A-B)n-CONH2, X-(A-B)n-O-CONH2, X-(A-B)n-NRCONH2, X-(CH2)m-heterocicloalquilo, X-(CH2)m-arilo y X-(CH2)m- heteroarilo con X que representa -O-C(O), -NH-C(O), NH-CS, -NH-CO-CH2-O-; -NH-CO-CH2-S-CH2-CO-NH-; -NH-CO-(CH2)2-SO2-; -NH-CO-CH2-N(CH3)-CO-; A y B representan un enlace sencillo, CH2, CH-alquilo, CH-aralquilo, n = 1,2 y m = 0, 1; R2 y R'2 representan H, halogeno, CF3, nitro, ciano, alquilo, hidroxi, mercapto, amino, alquilamino, dialquilamino, alcoxi, alquiltio, carboxi libre o esterificado por un radical alquilo, carboxamida, CO-NH(alquilo) y NH-COalquilo; p= 1 a 4 y p'= 1 a 3; L representa un enlace sencillo, CH2, C(O), O, S o NH, estando todos estos radicales sustituidos opcionalmente; estando estos productos en todas las formas isomeras y formas de sales, como medicamentos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0609331A FR2907453B1 (fr) | 2006-10-24 | 2006-10-24 | Nouveaux derives du fluorene,compositions les contenant et utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
AR063507A1 true AR063507A1 (es) | 2009-01-28 |
Family
ID=38069221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104666A AR063507A1 (es) | 2006-10-24 | 2007-10-23 | Derivados del fluoreno, composiciones que los contienen y uso como anticancerigenos |
Country Status (23)
Country | Link |
---|---|
US (1) | US8163750B2 (es) |
EP (1) | EP2078009B1 (es) |
JP (1) | JP5431944B2 (es) |
KR (1) | KR20090080948A (es) |
CN (1) | CN101528735A (es) |
AR (1) | AR063507A1 (es) |
AU (1) | AU2007310767A1 (es) |
BR (1) | BRPI0718202A2 (es) |
CA (1) | CA2664115A1 (es) |
CL (1) | CL2007003046A1 (es) |
CO (1) | CO6160311A2 (es) |
CR (1) | CR10690A (es) |
EA (1) | EA200970400A1 (es) |
FR (1) | FR2907453B1 (es) |
IL (1) | IL197887A0 (es) |
MA (1) | MA30904B1 (es) |
MX (1) | MX2009004049A (es) |
NO (1) | NO20091972L (es) |
PE (1) | PE20081261A1 (es) |
TN (1) | TN2009000086A1 (es) |
TW (1) | TW200825083A (es) |
UY (1) | UY30667A1 (es) |
WO (1) | WO2008049994A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
AU2010266570A1 (en) * | 2009-06-30 | 2012-01-19 | Siga Technologies, Inc. | Treatment and prevention of Dengue virus infections |
AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
DE102009054302A1 (de) * | 2009-11-23 | 2011-05-26 | Merck Patent Gmbh | Chinazolinderivate |
CN113521394A (zh) * | 2020-04-13 | 2021-10-22 | 浙江华臻医疗器械有限公司 | 一种脱细胞血管基质及其制备方法 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2476087A1 (fr) | 1980-02-18 | 1981-08-21 | Roussel Uclaf | Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkyl-thiomethyl 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments |
US7439359B2 (en) | 2000-11-02 | 2008-10-21 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
WO2003041643A2 (en) | 2001-11-09 | 2003-05-22 | Conforma Therapeutics Corporation | Hsp90-inhibiting zearalanol compounds and methods of producing and using same |
EP1521625B1 (en) | 2002-07-11 | 2009-03-11 | GEA BGR Energy System India Ltd. | A debris filter with a rotating debris extractor |
GB0227948D0 (en) | 2002-11-29 | 2003-01-08 | Cipla Ltd | Pharmaceutical combinations comprising b-2 adrenoreceptor agonists and xanthines |
GB0228417D0 (en) | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
WO2004072081A1 (en) | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
US20040163196A1 (en) | 2003-02-21 | 2004-08-26 | Mckenzie Rebecca Anne | Dusting-cleaning sleeve |
GB0309637D0 (en) | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
US7241754B2 (en) | 2003-06-13 | 2007-07-10 | Kosan Biosciences, Inc. | 2-Desmethyl ansamycin compounds |
GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
AU2004251949B2 (en) | 2003-06-27 | 2009-05-07 | Kyowa Hakko Kirin Co., Ltd. | Hsp90 family protein inhibitors |
AU2004200774A1 (en) | 2003-07-07 | 2005-01-27 | Holyrood Exports Pty Ltd | Padlock Protector |
WO2005006322A1 (ja) | 2003-07-11 | 2005-01-20 | Konica Minolta Opto, Inc. | 光ピックアップ装置、光ピックアップ装置に用いられる光学素子、及び光学素子の製造方法 |
EP1675861B1 (en) | 2003-08-29 | 2015-12-23 | Vernalis (R&D) Ltd. | Pyrimidothiophene compounds |
BRPI0414533A (pt) * | 2003-09-18 | 2006-11-07 | Conforma Therapeutics Corp | composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90 |
GB0323810D0 (en) | 2003-10-10 | 2003-11-12 | Cancer Rec Tech Ltd | Pyridothiophene compounds |
US6855705B1 (en) | 2003-11-12 | 2005-02-15 | Kosan Biosciences, Inc. | 11-O-methylgeldanamycin compounds |
DE10354133A1 (de) | 2003-11-19 | 2005-06-23 | Phoenix Ag | Fördergurt |
RU2484086C9 (ru) | 2003-12-23 | 2013-08-20 | Инфинити Дискавэри, Инк. | Аналоги бензохинонсодержащих ансамицинов (варианты), способ их получения, фармацевтическая композиция (варианты) и способ лечения рака (варианты) |
US20060019941A1 (en) | 2003-12-23 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Analogs of benzoquinone-containing ansamycins and methods of use thereof |
US7491701B2 (en) | 2004-01-27 | 2009-02-17 | Boys Town National Research Hospital | Peptides that bind to HSP90 proteins |
JP2005225787A (ja) | 2004-02-12 | 2005-08-25 | Nippon Kayaku Co Ltd | Hsp90阻害剤 |
GB0416168D0 (en) | 2004-07-20 | 2004-08-18 | Vernalis Cambridge Ltd | Pyrmidothiophene compounds |
US7342093B2 (en) | 2004-07-23 | 2008-03-11 | University Of Massachusetts | Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins |
US20090039811A1 (en) | 2004-07-27 | 2009-02-12 | Patrick Chene | Inhibitors of HSP90 |
PE20060572A1 (es) | 2004-07-27 | 2006-06-27 | Novartis Ag | Compuestos de benzoimidazolona como inhibidores de hsp90 |
KR101045324B1 (ko) | 2004-08-11 | 2011-06-30 | 한국생명공학연구원 | 젤다나마이신 유도체 및 그 생합성 방법 |
DE102004039280A1 (de) | 2004-08-13 | 2006-02-23 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole |
US7208630B2 (en) | 2004-10-27 | 2007-04-24 | University Of Kansas | Heat shock protein 90 inhibitors |
WO2006050477A2 (en) | 2004-11-03 | 2006-05-11 | K2 Concepts | Anti-microbial compositions and methods of making and using the same |
AU2005301957B2 (en) | 2004-11-03 | 2012-02-23 | Department Of Health And Human Services | Novobiocin analogues as anticancer agents |
JP4954083B2 (ja) | 2004-11-18 | 2012-06-13 | シンタ ファーマスーティカルズ コーポレイション | Hsp90活性を調節するトリアゾール化合物 |
FR2880540B1 (fr) | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
GB0501535D0 (en) | 2005-01-25 | 2005-03-02 | Vernalis R&D Ltd | Pyrimidothiophene compounds |
US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
DE102005007304A1 (de) | 2005-02-17 | 2006-08-24 | Merck Patent Gmbh | Triazolderivate |
FR2882361A1 (fr) | 2005-02-22 | 2006-08-25 | Aventis Pharma Sa | Nouveaux derives de 3-aryl-1,2-benzisoxazole, compositions les contenant et leur utilisation |
BRPI0607739A2 (pt) | 2005-02-25 | 2009-09-29 | Serenex Inc | derivados de tetraidroindolona e tetraidroindazolona, composição compreendendo os mesmos e uso relacionado |
WO2006090094A1 (en) | 2005-02-28 | 2006-08-31 | Vernalis R & D Ltd | Pyrimidothiophene compounds for use as hsp90 inhibitors |
DE102005009440A1 (de) | 2005-03-02 | 2006-09-07 | Merck Patent Gmbh | Thienopyridinderivate |
CN101160291B (zh) | 2005-03-09 | 2012-09-05 | 日本化药株式会社 | 作为hsp90抑制剂的三唑衍生物 |
EP1863769A4 (en) | 2005-03-11 | 2009-03-18 | Univ Colorado | HSP90 INHIBITORS, METHOD FOR THE PRODUCTION THEREOF AND THEIR APPLICATIONS |
JP2008137894A (ja) | 2005-03-22 | 2008-06-19 | Nippon Kayaku Co Ltd | 新規なアセチレン誘導体 |
EP1869027A4 (en) | 2005-03-30 | 2010-06-23 | Conforma Therapeutics Corp | ALKYNYL-PYRROLOPYRIMIDINES AND CORRESPONDING ANALOGS AS HSP90 INHIBITORS |
GB2423328B (en) | 2005-04-09 | 2007-02-28 | Louver Lite Ltd | Window blind system |
CN101155915B (zh) | 2005-04-11 | 2013-12-04 | 克鲁塞尔荷兰公司 | 利用超滤进行病毒纯化 |
FR2885904B1 (fr) * | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
-
2006
- 2006-10-24 FR FR0609331A patent/FR2907453B1/fr not_active Expired - Fee Related
-
2007
- 2007-10-17 WO PCT/FR2007/001703 patent/WO2008049994A1/fr active Application Filing
- 2007-10-17 KR KR1020097008314A patent/KR20090080948A/ko not_active Application Discontinuation
- 2007-10-17 AU AU2007310767A patent/AU2007310767A1/en not_active Abandoned
- 2007-10-17 CN CNA2007800397476A patent/CN101528735A/zh active Pending
- 2007-10-17 EA EA200970400A patent/EA200970400A1/ru unknown
- 2007-10-17 BR BRPI0718202-3A patent/BRPI0718202A2/pt not_active Application Discontinuation
- 2007-10-17 CA CA002664115A patent/CA2664115A1/fr not_active Abandoned
- 2007-10-17 JP JP2009533896A patent/JP5431944B2/ja not_active Expired - Fee Related
- 2007-10-17 EP EP07858463.8A patent/EP2078009B1/fr active Active
- 2007-10-17 MX MX2009004049A patent/MX2009004049A/es not_active Application Discontinuation
- 2007-10-22 TW TW096139514A patent/TW200825083A/zh unknown
- 2007-10-23 CL CL200703046A patent/CL2007003046A1/es unknown
- 2007-10-23 AR ARP070104666A patent/AR063507A1/es unknown
- 2007-10-24 PE PE2007001446A patent/PE20081261A1/es not_active Application Discontinuation
- 2007-10-29 UY UY30667A patent/UY30667A1/es not_active Application Discontinuation
-
2009
- 2009-03-13 TN TN2009000086A patent/TN2009000086A1/fr unknown
- 2009-03-24 CR CR10690A patent/CR10690A/es not_active Application Discontinuation
- 2009-04-05 IL IL197887A patent/IL197887A0/en unknown
- 2009-04-24 CO CO09041714A patent/CO6160311A2/es unknown
- 2009-05-18 MA MA31893A patent/MA30904B1/fr unknown
- 2009-05-20 NO NO20091972A patent/NO20091972L/no not_active Application Discontinuation
- 2009-11-24 US US12/625,005 patent/US8163750B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
MX2009004049A (es) | 2009-04-28 |
UY30667A1 (es) | 2008-05-31 |
JP5431944B2 (ja) | 2014-03-05 |
NO20091972L (no) | 2009-05-20 |
US8163750B2 (en) | 2012-04-24 |
MA30904B1 (fr) | 2009-11-02 |
EP2078009A1 (fr) | 2009-07-15 |
CL2007003046A1 (es) | 2008-05-30 |
KR20090080948A (ko) | 2009-07-27 |
CR10690A (es) | 2009-07-23 |
EP2078009B1 (fr) | 2015-03-18 |
AU2007310767A1 (en) | 2008-05-02 |
FR2907453A1 (fr) | 2008-04-25 |
FR2907453B1 (fr) | 2008-12-26 |
JP2010507634A (ja) | 2010-03-11 |
TW200825083A (en) | 2008-06-16 |
IL197887A0 (en) | 2009-12-24 |
WO2008049994A1 (fr) | 2008-05-02 |
US20100130503A1 (en) | 2010-05-27 |
CN101528735A (zh) | 2009-09-09 |
EA200970400A1 (ru) | 2009-10-30 |
TN2009000086A1 (en) | 2010-08-19 |
PE20081261A1 (es) | 2008-10-15 |
BRPI0718202A2 (pt) | 2013-11-12 |
CO6160311A2 (es) | 2010-05-20 |
CA2664115A1 (fr) | 2008-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111225T1 (el) | Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c | |
CL2022001670A1 (es) | Inhibidores de proteínas kras mutantes | |
CY1117639T1 (el) | Φαρμακευτικες συνθεσεις βασιζομενες επι κρυσταλλικης μορφης i της 5-αζακυτιδινης | |
NO20071077L (no) | Fosfonatanaloger til HIV-inhibitorforbindelser | |
CY1118980T1 (el) | Στερεες μορφες ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου | |
AR063507A1 (es) | Derivados del fluoreno, composiciones que los contienen y uso como anticancerigenos | |
UY29549A1 (es) | Nuevos derivados del fluoreno, composiciones que los contienen y su utilización | |
CY1111212T1 (el) | Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ | |
AR077478A2 (es) | Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos | |
UY29468A1 (es) | Nuevos derivados de isoindoles, composiciones que los contienen, su preparación y sus utilizaciones farmacéuticas, especialmente como inhibidores de las actividades de la proteína chaperona hsp90. | |
CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
NI201000150A (es) | Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización. | |
CY1114238T1 (el) | 2,4 – δι (φαινυλαμινο) - πυριμιδινες χρησιμες στην αντιμετωπιση των νεοπλασματικων παθησεων, των φλεγμονωδων διαταραχων και των διαταραχων του ανοσοποιητικου συστηματος | |
ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
PA8792501A1 (es) | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. | |
NI200900076A (es) | Nuevos derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, método para su preparación, productos farmacéuticos que comprenden estos compuestos y su uso. | |
HN2009001145A (es) | Compuestos y composiciones como inhibidores de proteina quinasa | |
CL2004000849A1 (es) | Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras. | |
BR0307833A (pt) | Sìntese controlada de ziprasidona e suas composições | |
ECSP077270A (es) | Ácidos de tiazolo - naftilo | |
CO6280537A2 (es) | Nuevos derivados de pirroloindol inhibidores de hsp90 composiciones que los contienen y utilizacion | |
RS51694B (en) | NEW PERINDOPRIL AND PHARMACEUTICAL COMPOSITIONS CONTAINING THERE | |
NO20055612L (no) | Anti-inflammatoriske fosfonatforbindelser | |
NO20060896L (no) | Alfa-aminoamidderivater nyttige som antiinflammatoriske midler | |
CY1118967T1 (el) | Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |